Related references
Note: Only part of the references are listed.Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985
Ronald C. Elgersma et al.
MOLECULAR PHARMACEUTICS (2015)
A CXCR4-Targeted Site-Specific Antibody-Drug Conjugate
Sumith A. Kularatne et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2014)
Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials
X. Li et al.
ANNALS OF ONCOLOGY (2014)
Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30+ Peripheral T-Cell Lymphomas: Results of a Phase I Study
Michelle A. Fanale et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Analytical and bioanalytical technologies for characterizing antibody-drug conjugates
Stephen C. Alley et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2013)
Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics
Surinder Kaur et al.
BIOANALYSIS (2013)
Analytical methods for physicochemical characterization of antibody drug conjugates
Aditya Wakankar et al.
MABS (2011)
Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates
Jean Philippe Stephan et al.
BIOANALYSIS (2011)
Cell-based assays: fuelling drug discovery
Elisa Michelini et al.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2010)
Antibody-Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies
Laurent Ducry et al.
BIOCONJUGATE CHEMISTRY (2010)
Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
Ian E. Krop et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Potent antibody drug conjugates for cancer therapy
Peter D. Senter
CURRENT OPINION IN CHEMICAL BIOLOGY (2009)
Doxorubicin immunoconjugates containing bivalent, lysosomally-cleavable dipeptide linkages
GM Dubowchik et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2002)
Protease-mediated fragmentation of p-amidobenzyl ethers:: A new strategy for the activation of anticancer prodrugs
BE Toki et al.
JOURNAL OF ORGANIC CHEMISTRY (2002)
Share Paper
